| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 6,022,287 |
| Net loss | -19,764,713 |
| Prepaid expenses | -1,600,000 |
| Inventory | 8,940,201 |
| Due to related party | 6,875,556 |
| Accrued expenses | 8,458,554 |
| Accounts payable | 4,955,797 |
| Deferred income tax expense | 792,720 |
| Net cash provided by operating activities | 0 |
| Net change in cash and cash equivalents | 0 |
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)